STOCK TITAN

Co-Diagnostics, Inc. - CODX STOCK NEWS

Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.

Co-Diagnostics, Inc. (NASDAQ: CODX) is a pioneering molecular diagnostics company based in Sandy, Utah. The company is renowned for its unique, patented technology that significantly enhances the speed, performance, and cost-efficiency of DNA testing for a variety of diseases compared to traditional methods. Co-Diagnostics focuses on the development, manufacturing, and commercialization of its proprietary technologies through sales, development, and licensing agreements.

Co-Diagnostics’ core technology is protected by multiple patents and trade secrets, enabling revolutionary approaches in molecular diagnostics. These innovations have been utilized to develop a range of assays in the infectious disease sector, demonstrating the technology's exceptional capabilities. The company's patented inventions stem from advanced mathematical models designed by Dr. Brent C. Satterfield.

The firm’s product portfolio includes diagnostic tests for diseases such as tuberculosis, Zika, hepatitis B and C, malaria, dengue, and HIV. These tests utilize the detection and analysis of nucleic acid molecules (DNA or RNA) to provide accurate and efficient diagnostics. Co-Diagnostics also leverages its proprietary technology to create tests for its Co-Dx PCR platform, which includes at-home and point-of-care solutions.

One of the notable collaborations of Co-Diagnostics is its joint venture with CoSara Diagnostics Pvt Ltd in India. This partnership has led to regulatory clearance from India’s Central Drugs Standard Control Organization (CDSCO) for multiple diagnostic tests, including the SARAPLEX™ Influenza Multiplex (IFM) Test Kit, which differentiates between Influenza A and B strains.

Recently, Co-Diagnostics announced significant milestones, such as the opening of new manufacturing facilities in Salt Lake City, Utah, and Ranoli, India. These facilities will enhance the production of the company’s novel Co-Dx PCR Pro™ instrument and test cups, as well as the Co-Primers™ chemistry that is vital for its PCR diagnostic tests. The Salt Lake City facility, inaugurated with support from local dignitaries and business leaders, marks a critical step in expanding the company's production capabilities.

The company’s forward-looking strategies include submitting an Emergency Use Authorization (EUA) to the FDA for the Co-Dx PCR Pro™ instrument, mobile app, and COVID-19 test. This submission is part of Co-Diagnostics’ effort to decentralize PCR diagnostics and extend its reach to at-home and point-of-care settings. The company is also developing tests for tuberculosis, multiplex respiratory infections, and HPV, among others.

Co-Diagnostics’ financial performance and strategic initiatives are regularly discussed through conference calls and webcasts, involving key executives such as CEO Dwight Egan and CFO Brian Brown. The company remains committed to innovation and growth, aiming to provide accessible and high-quality diagnostic solutions worldwide.

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) has completed the principal design of a PCR test for the monkeypox virus, amid a multi-country outbreak. The test will leverage the Company's patented CoPrimer™ technology and proprietary software system. CEO Dwight Egan emphasized the need for prompt action against potential outbreaks, highlighting Co-Dx's mission to enhance access to affordable, high-quality molecular testing globally. The World Health Organization reported monkeypox cases in 18 non-endemic countries since May 13, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation at the H.C. Wainwright & Co. 2022 Global Investment Conference, scheduled for May 23-26 in Miami, Florida. CEO Dwight Egan will present on May 25 at 1:30 PM ET, discussing the company's recent performance and its new Co-Dx PCR Home Diagnostic Platform. Egan highlighted Florida's significance as a market, contributing over $28 million in revenue since the pandemic began. The conference aims to engage institutional investors and industry professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) reported record first-quarter revenue of $22.7 million and a diluted EPS of $0.34 for the period ending March 31, 2022. Revenue growth was driven mainly by sales of the Logix Smart™ COVID-19 Test. Gross profit rose to $19.4 million, reflecting an 85.5% gross margin. However, operating income slightly decreased to $9.8 million due to increased R&D expenses. Cash reserves increased to $97.4 million, providing a strong foundation for future growth. Despite positive results, management highlighted challenges in forecasting future COVID-19 test sales due to changing market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.9%
Tags
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation at the Medical Fair Brasil from May 3-6, 2022, in São Paulo. This international exhibition focuses on hospital and diagnostic supplies, attracting key healthcare professionals. Co-Dx will showcase its innovative molecular diagnostic technologies, including a new point-of-care rapid PCR diagnostics platform. The event offers an opportunity for Company representatives to connect directly with decision-makers in healthcare, enhancing product visibility and potential sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company, announced that it will release its first quarter 2022 financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. EDT to discuss these results with analysts and investors. Key management, including CEO Dwight Egan and CFO Brian Brown, will participate in the call. The call will be accessible via the company's website and will also be recorded for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, from April 23-26, 2022. This congress will gather over 14,000 experts to discuss advances in clinical microbiology and infectious diseases. Co-Dx aims to engage potential international customers and showcase its upcoming rapid PCR diagnostics platform. The event will feature both onsite and online sessions, enhancing accessibility for attendees. For more details, visit ECCMID's official site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
conferences
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, has received clearance from India's Central Drugs Standard Control Organization (CDSCO) to manufacture and sell the SARAQ™ Hepatitis C Viral Load Kit as an in vitro diagnostic. This new real-time PCR test is crucial for assessing responses to antiviral treatments for Hepatitis C, a disease causing nearly 300,000 deaths annually. With over 58 million people affected globally, the test represents an essential addition to CoSara's growing diagnostics portfolio, enhancing patient care in regions with high disease burdens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) reported record full-year revenue of $97.9 million for 2021, up $23.3 million year-over-year, driven by sales of Logix Smart™ COVID-19 tests. Gross profit increased to $86.3 million, representing 88.2% of revenue. Net income was $36.7 million, down from $42.5 million in 2020. The company completed two strategic acquisitions and revealed a new at-home PCR diagnostic platform. Looking ahead, Q1 2022 revenue is projected between $21.0 million and $22.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.6%
Tags
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, will present its YourTest™ PCR device at the 3rd Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference on March 23-24, 2022, in London, England. CEO Dwight Egan will discuss the device on March 23rd at 14:00 GMT. The conference focuses on advancements in diagnostic testing for medical viruses, particularly Covid-19. Co-Diagnostics aims to enhance global access to care and innovation in diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced the enhancement of its Scientific Advisory Board (SAB) by adding renowned experts in molecular diagnostics. New members include Dr. Carl Wittwer as Chairman, along with Dr. Karen C. Carroll, Dr. Noriko Kusukawa, and Dr. Anne Wyllie. CEO Dwight Egan emphasized that their expertise will aid the company's growth and market expansion. The press release highlights the impressive qualifications of the new advisors, with many holding significant patents and research contributions in the field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
management

FAQ

What is the current stock price of Co-Diagnostics (CODX)?

The current stock price of Co-Diagnostics (CODX) is $0.73 as of December 20, 2024.

What is the market cap of Co-Diagnostics (CODX)?

The market cap of Co-Diagnostics (CODX) is approximately 23.6M.

What does Co-Diagnostics, Inc. specialize in?

Co-Diagnostics, Inc. specializes in molecular diagnostics with unique, patented technology for faster, more efficient DNA testing for various diseases.

Where is Co-Diagnostics headquartered?

Co-Diagnostics is headquartered in Sandy, Utah, USA.

What diseases can Co-Diagnostics' tests diagnose?

Co-Diagnostics offers tests for diseases such as tuberculosis, Zika, hepatitis B and C, malaria, dengue, and HIV.

What is the Co-Dx PCR platform?

The Co-Dx PCR platform includes at-home and point-of-care diagnostic solutions, designed to detect and analyze nucleic acid molecules (DNA or RNA).

What recent achievements has Co-Diagnostics made?

Co-Diagnostics recently opened new manufacturing facilities in Salt Lake City and India, enhancing production capabilities for its PCR platform and test kits.

What is the CoSara Diagnostics joint venture?

CoSara Diagnostics is a joint venture between Co-Diagnostics and Sarabhai Group in India, focused on manufacturing and selling diagnostic tests in the Indian market.

What are Co-Primers?

Co-Primers are patented oligonucleotides used in Co-Diagnostics' PCR tests to enhance accuracy and performance.

What regulatory clearances has Co-Diagnostics received in India?

The company's joint venture with CoSara has received CDSCO clearance for multiple diagnostic tests, including influenza and tuberculosis.

What is the FDA status of Co-Diagnostics' products?

Co-Diagnostics has submitted an EUA to the FDA for its Co-Dx PCR Pro™ instrument and COVID-19 test, aiming for future at-home and point-of-care use.

Who are the key executives at Co-Diagnostics?

Key executives include Dwight Egan (CEO) and Brian Brown (CFO).

Co-Diagnostics, Inc.

Nasdaq:CODX

CODX Rankings

CODX Stock Data

23.60M
29.79M
6.7%
13.96%
0.72%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SALT LAKE CITY